BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize targeted heat therapy to treat cancer, today announced growing interest in hyperthermia at the 2012 international conference of the American Society for Radiation Oncology (ASTRO). ASTRO is the largest radiation oncology society in the world, and the annual conference is the premier worldwide scientific meeting in radiation oncology. The theme of the 2012 meeting was “Advancing Patient Care Through Innovation.”
BSD offers technologically innovative products that provide targeted heat therapy for the treatment of cancer. Hyperthermia has been shown to be the most potent radiosensitizing agent known to date and has demonstrated the ability to increase the effectiveness of radiation and many chemotherapeutic agents for certain tumors.
“Exhibiting at ASTRO allowed BSD to showcase the Company’s hyperthermia technology to interested physicians and distributors throughout the world,” stated Harold R. Wolcott, President of BSD Medical. “We were pleased with the increased level of interest in hyperthermia shown by both the U.S. and the international medical community and distributors.”
ASTRO is the largest radiation oncology organization of its kind and has more than 10,000 members. Their members include radiation oncologists, radiation oncology nurses, medical physicists, radiation therapists, dosimetrists and biologists, the medical professionals that are part of the medical teams that treat more than 1 million cancer patients each year. ASTRO is committed to excellence in patient care through a team-based approach to treatment.
About the BSD Hyperthermia Systems
The BSD-500 Hyperthermia System (BSD-500) is used to deliver therapeutic, targeted heat therapy (hyperthermia) using either non-invasive (external) or interstitial (internal) applicators. The BSD-500 has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), which is the standard FDA approval required to market Class III medical devices in the United States, for the use of hyperthermia alone or in conjunction with radiation therapy for the treatment of certain tumors. Clinical studies have shown that hyperthermia delivered using the BSD-500 can significantly increase the effectiveness of radiation therapy without a significant increase in toxicity for certain tumors.
The BSD-2000 – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The BSD-2000 also has CE (Conformité Européenne) Marking approval for the commercial sale in Europe. CE Marking approval is also recognized in many countries outside of the EU.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.